Can a 10-Session program help older adults with mental illness overcome negative beliefs about aging?

NCT ID NCT07690098

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This pilot study tests a 10-session group program called AgingUP, designed for adults aged 50 and older living with severe mental illness. The program uses cognitive-behavioral and self-compassion techniques to help participants challenge negative beliefs about aging and mental illness. Researchers will compare participants who take the program with those receiving usual care to see if it reduces self-ageism and self-stigma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AgingUP (Self-Ageism Reduction Program)
What this could lead to
If effective, this program could offer a new way to improve self-perception and quality of life for older adults with severe mental illness.
What could go wrong
This is a small pilot study with only 36 participants, so results may not apply broadly. The program may not produce lasting changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Oct 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age: ≥ 50 years (preventive/therapeutic focus on early and late aging in Severe Mental Illness). Diagnosis: Having a clinical diagnosis of Severe Mental Illness (SMI) such as schizophrenia, bipolar disorder, psychotic spectrum disorders, or severe affective disorders. Active Treatment: Currently receiving psychiatric or psychosocial treatment in a mental health center, rehabilitation unit, or community service. Legal Status: Not having a court-appointed legal representative. Voluntariness: Participation must be completely voluntary, without coercion or obligation. Language and Communication: Able to communicate in the language used for the study/intervention (e.g., Spanish). Availability: Willing to attend the scheduled sessions and activities according to the study/intervention design. Exclusion Criteria: * Severe Cognitive Impairment: Presence of advanced dementia or severe neurodegenerative disease that limits understanding or informed consent. Active Psychiatric Crisis: Experiencing an acute psychotic episode, manic crisis, or severe depression with high suicide risk at the time of assessment. Severe Medical Conditions: Having medical illnesses that prevent participation in study activities. Concurrent Study Participation: Participation in another ongoing study that may interfere with the objectives of this intervention. Legal Incapacity: Having a legal incapacity that prevents free and voluntary participation. Severe Cognitive Difficulties: Difficulties that significantly impair understanding of information or participation in group or digital activities. Language Barrier: Inability to understand the language in which the intervention is conducted, limiting comprehension of study content. Informed Consent: Failure to sign the informed consent form or expressing significant doubts about voluntary participation. Lack of Availability: Unwillingness or inability to attend the sessions according to the structure and duration of the study. Concurrent Participation: Participation in another study that could interfere with the goals of this intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mental disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UNINPSI

    Madrid, Madrid, 28036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.